Treatment-related chronic myelogenous leukemia.
Treatment-related (Tr) AML and MDS after chemotherapy, radiotherapy, or the combination of both have been well characterized. However, tr-CML seems to differ from these better-known entities in frequency, clinical course, and prognosis. Tr-CML cannot be distinguished from de novo CML cytogenetically, and, in contrast to tr-AML and tr-MDS, typical chromosomal aberrations related to tr-CML have not been described. Treatment-related CML is a late effect of cytotoxic or immunosuppressive therapy which might be increasingly recognized due to a higher number of patients treated with intensive therapy regimens. We review here the available data on incidence of tr-CML as well as the affected individual's characteristics with regard to different treatment options in malignant and nonmalignant diseases.
Waller
C F
CF
Department of Internal Medicine 1, Hematology/Oncology, Albert-Ludwigs-University, Freiburg Medical Center, Freiburg, Germany. Waller@mm11.ukl.uni-freiburg.de
Fetscher
S
S
Lange
W
W
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000209:etiology*; D008297:Male; D008875:Middle Aged; D011878:Radiotherapy / Q000009:adverse effects*
D000970:Antineoplastic Agents